1. late stages clinical trials management, proof-of-concept and safety profile studies
2. market research with unmatched accuracy and outsourced R&D (dossier development)
3. state-of the-art pharmaceutical cGMP-compliant manufacturing
4. scientific marketing & promotion and pharmaceuticals launches
5. wholesale & distribution
6. retail pharmacies management, and much more

The group flagship and manufacturing arm Tchaikapharma is the growth driver and profitability lynchpin keeping sharp eye on both in-licensing rights from the majors and introducing branded generics. Local production for 12 originals in CVS, CNS, diabetes, respiratory disease and 16 generics presently on the market will be followed by 33 new marketing authorizations in 2006 allowing for clinical coverage and tailor-made therapeutic baskets in all chief diagnoses. Every new product to become a leader in its respective therapeutic class within the first year after registration is already an established rule.

With unmatched computing power, warehouse management and order processing capacity, Commercial League National Pharma Center, Inc. enjoys an overall 38% market share in Bulgaria and Macedonia. Premier partner of the overwhelming majority of multinationals and the major supplier of the public health sector (MoH tenders 35% market share in 2005, hospitals over 65%, NHIF ca. 52%) the group’s priority targets are the further portfolio extension and international geographic expansion in the next three years.

CL BioPharma has achieved complete visibility after 3 years running on CL Softy System— SAP R/3 customized application software. Revenue (ˆ173mn) and EBITDA (ˆ16.8mn) growth in 2005 continue to outperform the Europe’s best growth markets increasingly with an annual pace of 40% (’04-‘05) and 65% (’04-‘05) respectively. In 2006, the growth is targeted at the mid double-digit range on an IFRS conversion basis (KPMG London).